Citi analyst Daniel Grosslight raised the firm’s price target on McKesson to $620 from $575 and keeps a Buy rating on the shares. The analyst remains generally positive on the distributors heading into the Q1 reports, but cautions that this will be a difficult quarter from a comp perspective. Namely, GLP-1 growth will slow materially and the distributors will see limited benefit from commercial COVID vaccines, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- Cardinal Health price target lowered to $110 from $118 at Evercore ISI
- McKesson won OptumRx contract lost by Cardinal, says Evercore
- Early notable gainers among liquid option names on April 10th
- McKesson price target raised to $570 from $510 at Argus
- Notable companies reporting before tomorrow’s open
